HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Samsung Bioepis Co., Ltd.


Latest From Samsung Bioepis Co., Ltd.

Amgen Snatches First FDA Approval For Soliris Biosimilar

Amgen has established its frontrunner position in the eculizumab race with a recent FDA approval and an interchangeability designation. Meanwhile, a US District Court has sided with runner-up Samsung Bioepis.

Approvals Biosimilars

US Eylea Biosimilar Approvals Set Up Competition On Aflibercept

Biocon and Biogen have received simultaneous US approvals for aflibercept biosimilar rivals to Eylea, with both products also receiving interchangeability designations. However, launches may have to wait while IP issues are resolved.

Biosimilars Approvals

Celltrion Offers 85% Discount For Adalimumab Biosimilar In US

Celltrion joins a number of other adalimumab competitors with dual pricing strategies as Humira biosimilars finally gain some traction in the US market.

United States Biosimilars

Finance Watch: Verona Accesses Up To $650m As Ensifentrine Approval Deadline Nears

Public Company Edition: Verona Pharma arranged up to $400m in new debt and up to $250m in revenue-related financing ahead of its COPD drug launch. Also, Organon, Sobi and Pacira priced $1bn, $275.1m and $250m note sales, respectively. Marinus, Emergent and Ginkgo cut jobs.

Financing Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • Samsung Biologics
    • Samsung Bioepis JV
    • Samsung Bioepis BR Pharmaceutical LTDA